Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alkermes (ALKS)

Alkermes to acquire Avadel for $18.50 cash per share plus CVR, up to $2.1 billion

Neutral Impact 5 of 5 m&a Written later

Alkermes agreed to acquire Avadel Pharmaceuticals through a court-sanctioned Irish scheme of arrangement, with Avadel becoming a wholly owned subsidiary. Avadel shareholders would receive $18.50 per share in cash plus a contingent value right worth up to an additional $1.50 per share, for total consideration of up to $20.00 per share. The deal is expected to close in the first quarter of 2026, subject to Avadel shareholder approval, a High Court sanction and US antitrust clearance, and Alkermes expects it to be immediately accretive.

Key points

  • Cash consideration of $18.50 per Avadel share, plus a CVR of up to $1.50 per share tied to FDA approval of LUMRYZ for idiopathic hypersomnia in adults by the end of 2028
  • Equity value of approximately $2.1 billion, a 12% premium to Avadel's October 21, 2025 closing price and a 38% premium to its three-month weighted average price
  • Alkermes expects to fund the deal with cash on hand and new debt; J.P. Morgan has provided fully committed financing
  • Expected close in the first quarter of 2026; termination fee payable by Avadel is capped at 1% of total cash consideration

The filing

CompanyAlkermes (ALKS)
Form8-K, current report
Filed with the SECOct 22, 2025, 9:09 AM ET
Accession number0001193125-25-245852

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations2.03 New Direct Financial Obligation7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.